ABSTRACT
BACKGROUND: Premenstrual dysphoric disorder (PMDD) is a condition causing severe emotional, physical, and behavioral symptoms before menstruation. It greatly hinders daily activities, affecting academic and interpersonal relationships. Attention is not given to premenstrual disorders among female students in higher education. As a result, students are susceptible to stress, and their academic success is influenced by various factors, including their menstrual cycle, and the long-term outcomes and consequences are poorly researched. Even though PMDD has a significant negative impact on student's academic achievement and success limited research has been conducted in low- and middle-income countries including Ethiopia, especially in the study setting. Therefore, a study is needed to assess premenstrual dysphoric disorder and associated factors among regular undergraduate students at Hawassa University. METHODS: An institutional-based cross-sectional study was conducted among 374 regular undergraduate female students at Hawassa University, College of Medicine and Health Sciences. A self-administered structured premenstrual symptoms screening tool for adolescents was used to assess premenstrual dysphoric disorder. The collected data were loaded into a statistical package for the social science version 25 and analyzed using it. Both bivariate and multivariate logistic regression were used to identify factors associated with premenstrual dysphoric disorder. Each independent variable was entered separately into bivariate analysis, and a variable with a p-value less than 0.25 were included in the multivariate analysis to adjust the possible confounders. Statistically significant was declared at a 95% confidence interval when variable with a p-value less than 0.05 in the multivariate analysis with premenstrual dysphoric disorder. RESULTS: The magnitude of premenstrual dysphoric disorder in this study was 62.6% (95% CI 57.4-67.5). Having severe premenstrual pain (AOR = 6.44;95%CI 1.02-40.73), having irregular menstrual cycle (AOR = 2.21; 95% CI 1.32-3.70), students who had poor social support (AOR = 5.10;95%CI, (2.76-12.92) and moderate social support (AOR = 4.93;95%CI (2.18-11.18), and students who used contraception (AOR = 3.76;95%CI, 2.21-6,40) were statistically significant factors with the outcome variable. CONCLUSION: The prevalence of premenstrual dysphoric disorder was high as compared to other studies. There was a strong link between irregular menstrual cycle, severe menstrual pain (severe dysmenorrhea), poor social support, and contraception use with premenstrual dysphoric disorder. This needs early screening and intervention to prevent the complications and worsening of the symptoms that affect students' academic performance by the institution.
Subject(s)
Premenstrual Dysphoric Disorder , Students , Humans , Female , Ethiopia/epidemiology , Cross-Sectional Studies , Students/statistics & numerical data , Students/psychology , Universities , Young Adult , Premenstrual Dysphoric Disorder/epidemiology , Premenstrual Dysphoric Disorder/psychology , Adolescent , Adult , Risk Factors , Surveys and QuestionnairesABSTRACT
BACKGROUND: Premenstrual dysphoric disorder is characterised by symptoms confined to the premenstrual phase of the menstrual cycle. Confirmed diagnosis requires prospective monitoring of symptoms over two cycles, otherwise the diagnosis is provisional. We aimed to measure the point prevalence of premenstrual dysphoric disorder. METHODS: We searched for studies of prevalence using MEDLINE, EMBASE, PsycINFO and PubMed. For each study, the total sample size and number of cases were extracted. The prevalence across studies was calculated using random effects meta-analysis with a generalised linear mixed model. Potential sources of heterogeneity were explored by meta-regression and subgroup analyses. Pre-registration was with PROSPERO (CRD42021249249). RESULTS: 44 studies with 48 independent samples met inclusion criteria, consisting of 50,659 participants. The pooled prevalence was 3.2 % (95 % confidence intervals: 1.7 %-5.9 %) for confirmed and 7.7 % (95 % confidence intervals: 5.3 %-11.0 %) for provisional diagnosis. There was high heterogeneity across all studies (I2 = 99 %). Sources of heterogeneity identified by meta-regression were continent of sample (p < 0.0001), type of sample (community-based, university, high school) (p = 0.007), risk of bias (p = 0.009), and method of diagnosis (p = 0.017). Restricting the analysis to community-based samples using confirmed diagnosis resulted in a prevalence of 1.6 % (95 % confidence intervals: 1.0 %-2.5 %), with low heterogeneity (I2 = 26 %). LIMITATIONS: A small number of included studies used full DSM criteria in community settings. CONCLUSIONS: The point prevalence of premenstrual dysphoric disorder using confirmed diagnosis is lower compared with provisional diagnosis. Studies relying on provisional diagnosis are likely to produce artificially high prevalence rates.
Subject(s)
Premenstrual Dysphoric Disorder , Humans , Female , Premenstrual Dysphoric Disorder/epidemiology , Premenstrual Dysphoric Disorder/diagnosis , Prevalence , AdultABSTRACT
Up to 92 percent of Chinese women of reproductive age have pre-menstrual syndrome (PMS). The severe form of PMS (i.e. pre-menstrual dysphoric disorder [PMDD]) negatively affects women's everyday functioning and reproductive health. This study examined the relationships between menstrual, psychosocial characteristics and the risk of PMDD among young Chinese women. A cross-sectional online survey was conducted among Chinese university students in Hong Kong. Logistic regression was used to compute adjusted odds ratio (aOR) for the association of high-risk PMDD with menstrual and psychosocial characteristics. A total of 541 Chinese university students were recruited. Approximately 53 percent of female students were at high risk of developing PMDD. The high-risk PMDD group was significantly associated with a heavy volume of menstrual flow (aOR = 2.17, 95 percent CI 1.06-4.45), irregular menstrual cycle (1.72, 1.17-2.52), high dysmenorrhea (2.80, 1.95-4.04) and older ages of menarche (0.67, 0.45-0.98) in the menstrual characteristics. In the psychosocial characteristics, high-risk PMDD was significantly associated with symptoms of anxiety (2.19, 1.48-3.32) and depression (2.22, 1.48-3.32), high loneliness (1.94, 1.34-2.79) and low resilience (2.21, 1.52-3.23) levels. Additionally, resilience had a potential moderating effect on the associations between the high risk of PMDD and anxiety, depression and loneliness. The development and delivery of interventions that can enhance resilience and manage psychological distress would be beneficial for young Chinese women's reproductive health.
Subject(s)
Premenstrual Dysphoric Disorder , Premenstrual Syndrome , Female , Humans , Premenstrual Dysphoric Disorder/epidemiology , Premenstrual Dysphoric Disorder/diagnosis , Premenstrual Syndrome/epidemiology , Premenstrual Syndrome/diagnosis , Cross-Sectional Studies , Universities , Menstruation Disturbances/complications , Students , Menstrual CycleABSTRACT
OBJECTIVE: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) are experienced in the luteal phase among women of reproductive age and are known to affect quality of life. This study sought to determine the prevalence and correlates of PMS and PMDD in women aged 18-25 in Turkey. METHOD: A cross-sectional study was conducted between December 2022 and May 2023, which recruited 1125 female college students. A personal information form, the International Physical Activity Questionnaire, and the Premenstrual Syndrome Scale (PMSS) were administered. Participants who met criteria for PMS during three consecutive menstrual cycles based on the ACOG and PMSS scores were diagnosed as having PMS. Participants who met the criteria for PMDD during three consecutive menstrual cycles based on the DSM-V were diagnosed as having PMDD. Logistic regression analysis was used to determine correlates of PMS and PMDD. FINDINGS: PMS was found in 49.2% and PMDD in 48.0% of the participants. Women having a blood group type B compared to those with blood group type A were more likely to have PMS (OR = 151.8, 95% CI = 54.5-422.6). In addition, women with PMS were less likely to be physically active based on the metabolic equivalent of task score (OR = 0.99, 95% CI= 0.98-0.99). Menstrual cycle duration was also longer among those with PMDD (OR = 1.47, 95% CI= 1.25-1.72), as was daily caffeine intake (OR = 1.01, 95% CI= 1.00-1.01). PMDD score was also found to be associated with major depressive disorder (OR = 1.06,95% = 1.05-1.07). CONCLUSIONS: PMS and PMDD among young women in Turkey were associated with blood groups, MET scores, and other clinical characteristics that may help clinicians to identify these conditions.
Subject(s)
Blood Group Antigens , Depressive Disorder, Major , Premenstrual Dysphoric Disorder , Premenstrual Syndrome , Female , Humans , Adolescent , Young Adult , Adult , Premenstrual Dysphoric Disorder/diagnosis , Premenstrual Dysphoric Disorder/epidemiology , Quality of Life , Prevalence , Cross-Sectional Studies , Turkey/epidemiology , Premenstrual Syndrome/diagnosis , Premenstrual Syndrome/epidemiologyABSTRACT
Most women who menstruate experience various physical, psychological, and behavioral changes during the period between ovulation and menstruation. This study focuses on defining and diagnosing premenstrual disorders, distinguishing between premenstrual symptoms (PS), PMS, and premenstrual dysphoric disorder (PMDD). It highlights the prevalence of these conditions and their impact on women's quality of life, including social, occupational, and psychological aspects. Furthermore, the study examines the role of physical activity, particularly aerobic exercise, in managing premenstrual symptoms. Several systematic reviews are cited, suggesting that regular physical activity can effectively reduce both physical and psychological symptoms associated with PMS. In conclusion, the management of PMS involves a multifaceted approach, with exercises, dietary modifications, stress management, cognitive-behavioral therapy, and medications all playing roles. Physical activity, especially aerobic exercise, has been found to be an effective non-pharmacological therapy for alleviating PMS symptoms and improving overall well-being. However, more research is needed to determine the optimal type and dosage of exercise for individual women with PMS.
Subject(s)
Premenstrual Dysphoric Disorder , Premenstrual Syndrome , Female , Humans , Premenstrual Dysphoric Disorder/epidemiology , Premenstrual Dysphoric Disorder/therapy , Quality of Life , Premenstrual Syndrome/therapy , Exercise , PrevalenceABSTRACT
Premenstrual dysphoric disorder (PMDD) is a periodic psychiatric disorder with high prevalence in women of childbearing age, seriously affecting patients' work and life. Currently, the international first-line drugs for PMDD have low efficiency and increased side effects. Paeonol, a major component of the traditional Chinese medicine Cortex Moutan, has been applied in treating PMDD in China with satisfactory results, but the therapeutic mechanism is not fully understood. This study aims to evaluate the therapeutic effects and pharmacological mechanisms of paeonol on the main psychiatric symptoms and hippocampal damage in PMDD. We established a premenstrual irritability rat model by the resident-intruder paradigm and performed elevated plus maze and social interactions. And we employed the HE and Nissl staining techniques to observe the therapeutic effect of paeonol on hippocampal damage in PMDD rats. Subsequently, Elisa, qRT-PCR Array, Western Blotting, and cell models were utilized to elucidate the underlying molecular mechanisms through which paeonol intervenes in treating PMDD. In this study, we demonstrated the therapeutic effects of paeonol on irritability, anxiety, and social withdrawal behaviors in rats. In addition, we found that paeonol significantly reduced the serum corticosterone (CORT) level, improved hippocampal morphological structure and neuron number, and reduced hippocampal neuron apoptosis in PMDD rats. Paeonol reduced GRM5, GABBR2, ß-arrestin2, and GRK3 expression levels in hippocampal brain regions of PMDD rats and activated the cAMP/PKA signaling pathway. Inhibitor cell experiments showed that paeonol specifically ameliorated hippocampal injury by modulating the ß-arrestin2/PDE4-cAMP/PKA signaling pathway. The present study demonstrates, for the first time, that paeonol exerts a therapeutic effect on periodic psychotic symptoms and hippocampal injury in PMDD through inhibiting GRM5/GABBR2/ß-arrestin2 and activating cAMP-PKA signaling pathway. These findings enhance our understanding of the pharmacological mechanism underlying paeonol and provide a solid scientific foundation for its future clinical application.
Subject(s)
Premenstrual Dysphoric Disorder , Animals , Female , Rats , Acetophenones , Anxiety , Hippocampus/metabolism , Premenstrual Dysphoric Disorder/diagnosis , Premenstrual Dysphoric Disorder/epidemiology , Premenstrual Dysphoric Disorder/psychology , Receptors, GABA-B/metabolismABSTRACT
Background Pre-menstrual Syndrome and Pre-menstrual Dysphoric Disorder can have negative impact on medical students and remains mostly underdiagnosed. Different treatment modalities like medications (doctor-prescribed or self-medicated), and alternative therapies are used by students to cope with pre-menstrual symptoms. Objective To estimate the prevalence and severity of Premenstrual Syndrome and Premenstrual Dysphoric Disorder among medical students in Nepal along with its impact in their quality of life, their health seeking behavior and treatment modalities used to cope with these disorders. Method A cross-sectional study was conducted among female medical students studying MBBS in various medical colleges in Nepal using a self-administered questionnaire from September 2020 to March 2021. Result The prevalence of Premenstrual Syndrome and Premenstrual Dysphoric Disorder among female medical students in Nepal was 64% and 36.3% respectively as per this study. Among the areas impacted by premenstrual symptoms, concentration in class was the most affected (68.1%), followed by distress (64.6%). Only 7.3% of the responding participants sought medical consultation for their symptoms. Among those who suffered from at least one symptom for any length of time, 34.8% of participants reported of using at least one medication (either prescribed or selfmedication). Similarly, alternative remedies were used by 44.4% of the participants. Conclusion Premenstrual syndrome and premenstrual dysphoric disorder were found to be common in female medical students of Nepal. However, very few students sought medical consultation despite a significant impact in their academic and other activities. Self-medication and traditional therapies were common modalities used for treatment of premenstrual symptoms.
Subject(s)
Premenstrual Dysphoric Disorder , Premenstrual Syndrome , Students, Medical , Female , Humans , Premenstrual Dysphoric Disorder/diagnosis , Premenstrual Dysphoric Disorder/epidemiology , Nepal/epidemiology , Cross-Sectional Studies , Quality of Life , Premenstrual Syndrome/diagnosis , Premenstrual Syndrome/epidemiology , Premenstrual Syndrome/therapyABSTRACT
Premenstrual symptoms are characterized by unpleasant psychophysical symptoms that appear during the luteal phase before menstruation and interfere with a woman's quality of life. Premenstrual syndrome (PMS) is a pathological condition with premenstrual symptoms, of which premenstrual dysphoric disorder (PMDD) is a particularly severe psychological symptom. This study aimed to examine the gender differences in the diagnosis and treatment of PMS and PMDD among obstetricians and gynecologists (OB/GYNs) in Japan. Data were obtained from the survey conducted by the Japanese Society of Obstetrics and Gynecology. We used data from 1,257 of the 1,265 OB/GYNs who are engaged in PMS/PMDD practice and reported their gender. Multivariate regression analysis adjusted for propensity scores was performed. Female OB/GYNs were more frequently engaged in treating patients with PMS/PMDD than males [odds ratio (OR) 1.74; 95% confidence interval (CI) 1.36-2.21]. With regard to the diagnostic methods, more female OB/GYNs selected the two-cycle symptom diary than males (OR 2.88; 95% CI 1.80-4.60). Regarding treatment, fewer female OB/GYNs selected selective serotonin reuptake inhibitors as their first-line drug (OR 0.39; 95% CI 0.17-0.89). Gender differences were found in the selection of PMS/PMDD diagnosis and treatment methods among Japanese OB/GYNs.
Subject(s)
Premenstrual Dysphoric Disorder , Premenstrual Syndrome , Female , Humans , Cross-Sectional Studies , East Asian People , Gynecologists , Japan/epidemiology , Obstetricians , Premenstrual Dysphoric Disorder/diagnosis , Premenstrual Dysphoric Disorder/epidemiology , Premenstrual Dysphoric Disorder/therapy , Premenstrual Syndrome/diagnosis , Premenstrual Syndrome/epidemiology , Premenstrual Syndrome/therapy , Quality of Life , Sex Factors , Male , Health Knowledge, Attitudes, PracticeABSTRACT
BACKGROUND: Menstrual cycle (MC) disorders and MC-related symptoms can have debilitating effects on the health and performance of female athletes. As the participation of women in sports continues to increase, understanding the prevalence of a range of MC disorders and MC-related symptoms may guide preventive strategies to protect the health and optimise the performance of female athletes. OBJECTIVE: To examine the prevalence of MC disorders and MC-related symptoms among female athletes who are not using hormonal contraceptives and evaluate the assessment methods used to identify MC disorders and MC-related symptoms. METHODS: This systematic review was performed in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA). Six databases were searched until September 2022 for all original research that reported the prevalence of MC disorders and/or MC-related symptoms in athletes not using hormonal contraceptives, which included the definitions of the MC disorders examined, and the assessment methods used. MC disorders included amenorrhoea, anovulation, dysmenorrhoea, heavy menstrual bleeding (HMB), luteal phase deficiency (LPD), oligomenorrhoea, premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD). MC-related symptoms included any affective and physical symptoms related to the MC that do not cause significant personal, interpersonal or functional impairment. The prevalence data across eligible studies were combined, and all studies were qualitatively synthesised to evaluate the assessment methods and tools used to identify MC disorders and MC-related symptoms. The methodological quality of studies was assessed using a modified Downs and Black checklist. RESULTS: Sixty studies involving 6380 athletes were included. A wide range of prevalence was observed for all types of MC disorders, with a dearth of data on anovulation and LPD. Based on pooled data, dysmenorrhoea (32.3%; range 7.8-85.6%) was the most prevalent MC disorder. Studies reporting MC-related symptoms mostly examined the premenstrual and menstruation phases, where affective symptoms appeared more prevalent than physical symptoms. A larger proportion of athletes reported symptoms during the initial days of menstruation compared with the premenstrual phase. MC disorders and MC-related symptoms were retrospectively assessed using self-report methods in 90.0% of studies. Most studies (76.7%) in this review were graded as moderate quality. DISCUSSION: MC disorders and MC-related symptoms are commonplace among female athletes, warranting further research examining their impact on performance and preventive/management strategies to optimise athlete health. To increase the quality of future studies, researchers should adopt standardised definitions of MC disorders and assessment methods such as a combination of calendar counting, urinary ovulation tests and a mid-luteal phase serum progesterone measurement when assessing menstrual function. Similarly, standardised diagnostic criteria should be used when examining MC disorders such as HMB, PMS and PMDD. Practically, implementing prospective cycle monitoring that includes ovulation testing, mid-luteal blood sampling (where feasible) and symptom logging throughout the MC could support athletes and practitioners to promptly identify and manage MC disorders and/or MC-related symptoms. TRIAL REGISTRATION: This review has been registered in the PROSPERO database (CRD42021268757).
Subject(s)
Anovulation , Premenstrual Dysphoric Disorder , Premenstrual Syndrome , Female , Humans , Dysmenorrhea/epidemiology , Dysmenorrhea/complications , Prevalence , Prospective Studies , Anovulation/complications , Retrospective Studies , Menstrual Cycle , Premenstrual Syndrome/diagnosis , Premenstrual Syndrome/epidemiology , Premenstrual Syndrome/psychology , Menstruation Disturbances/epidemiology , Premenstrual Dysphoric Disorder/complications , Premenstrual Dysphoric Disorder/epidemiology , Athletes , Contraceptive AgentsABSTRACT
OBJECTIVE: To determine the frequency of Premenstrual Dysphoric Disorder (PMDD) in female medical students, and to compare the quality of life between those with and without PMDD. STUDY DESIGN: Descriptive Study. Place and Duration of the Study: Fatima Jinnah Medical University, Lahore, from November 2019 to April 2020. METHODOLOGY: The study included 635 female medical students from the third year to the final year of MBBS. Quality of life was measured by using the World Health Organization Quality of Life Brief (WHOQOL-BREF) Scale and PMDD was diagnosed as per DSM-V Diagnostic criteria. Data were entered and analysed by IBM SPSS version 23.0. Scores of 4 domains of the WHOQOL-BREF scale were compared between the female medical students with and without PMDD. A p-value of ≤0.05 was considered statistically significant. RESULTS: Significant proportion i.e., 12.1% (77) out of 635 female medical students had PMDD. There was a significant difference in the physical and psychological domains scores of the WHOQOL-BREF scale between healthy students and students with PMDD (p-value <0.001). CONCLUSION: The physical and Psychological aspects of quality of life are significantly lower in female medical students with PMDD. KEY WORDS: WHOQOL-BREF, Premenstrual dysphoric disorder, Female medical students.
Subject(s)
Premenstrual Dysphoric Disorder , Premenstrual Syndrome , Students, Medical , Female , Humans , Premenstrual Dysphoric Disorder/epidemiology , Premenstrual Dysphoric Disorder/psychology , Premenstrual Syndrome/epidemiology , Premenstrual Syndrome/diagnosis , Premenstrual Syndrome/psychology , Quality of Life , UniversitiesABSTRACT
OBJECTIVE: Premenstrual syndrome (PMS) is a clinical condition with physical and psychological symptoms affecting female students' quality of life, social activity, and school performance. Since most studies have focused on adult women, this study aimed to evaluate the prevalence of moderate-severe PMS, premenstrual dysphoric disorder (PMDD), and their related factors in high school students. METHODS: The participants of this cross-sectional study, conducted in 2019, were 900 high school students in Sari, north of Iran. They were selected by census method from six high schools. Data were collected using Premenstrual Syndrome Screening Tool and General Health Questionnaire. RESULTS: The prevalence of moderate-severe PMS and PMDD were 33.9% and 12.3%, respectively. According to the logistic regression model, dysmenorrhea was significantly associated with a higher prevalence of moderate-severe PMS [adjusted odds ratio (AOR) 2.356, confidence interval (CI): 1.706-3.254, p < 0.0001] and PMDD (AOR: 1.924, CI: 1.186-3.120, p = 0.0008). Moreover, optimal general health was associated with a lower prevalence of moderate-severe PMS (AOR: 0.326, CI: 0.221-0.480, p < 0.0001) and PMDD (AOR: 0.309, CI: 0.161-0.593, p < 0.0001). The findings revealed that a family history of PMS and adding excess salt to the food were associated with a higher prevalence of PMDD (p < 0.05). CONCLUSION: Although many high school students do not meet the criteria for PMDD, many experience PMS, which could be diminished with proper diet and improved general health.
Subject(s)
Premenstrual Dysphoric Disorder , Premenstrual Syndrome , Adult , Female , Humans , Premenstrual Dysphoric Disorder/epidemiology , Cross-Sectional Studies , Quality of Life , Prevalence , Premenstrual Syndrome/diagnosis , Premenstrual Syndrome/epidemiology , Premenstrual Syndrome/psychology , StudentsABSTRACT
INTRODUCTION: Premenstrual dysphoric disorder (PMDD) and female sexual dysfunction (FSD) are 2 prevalent illnesses in women that cause distress and affect quality of life. There are plausible biological, social, and psychological links between these 2 conditions. Nevertheless, few studies have examined sexual function in women with PMDD. OBJECTIVES: In this narrative review we summarize the existing literature on sexual function in women with PMDD and with the broader diagnostic classification of premenstrual syndrome and discus the differences between PMDD and more general premenstrual symptomatology, as well as why studying sexual function specifically in PMDD is necessary. We explored reasons why these 2 illnesses may be comorbid and the importance of studying sexual function in this population of women. METHODS: PubMed literature searches were conducted using relevant keywords. RESULTS: Currently, there are few studies examining PMDD and FSD, and the studies available have significant methodologic limitations. CONCLUSIONS: Investigation of sexual function in women with PMDD is needed. Awareness of the comorbidities for PMDD and FSD can allow implementation of targeted interventions for women suffering from these disorders.
Subject(s)
Premenstrual Dysphoric Disorder , Premenstrual Syndrome , Female , Humans , Premenstrual Dysphoric Disorder/diagnosis , Premenstrual Dysphoric Disorder/epidemiology , Quality of Life , Premenstrual Syndrome/diagnosis , Premenstrual Syndrome/epidemiology , Premenstrual Syndrome/psychology , Anxiety , ComorbidityABSTRACT
AIM: The study aimed to determine potential risk factors associated with Premenstrual Syndrome and Premenstrual Dysphoric Disorder. METHODS: Three hundred two female student participants who were 18-45 years old completed a questionnaire including demographic characteristics, lifestyle factors, and a Vietnamese Premenstrual Syndrome Screening Tool. We then followed up participants during at least two menstrual cycles using the Daily Record of Severity of Problems. The Premenstrual Syndrome and Premenstrual Dysphoric Disorder diagnosis was established using The Carolina Premenstrual Assessment Scoring System, based on the American College of Obstetrics and Gynecology and Diagnostic and Statistical Manual of Mental Disorders. RESULTS: According to the Carolina Premenstrual Assessment Scoring System, 35 out of 302 students (11.6%; 95%CI: 8.2-15.7%) met the diagnosis of PMS (31 students) or PMDD (4 students). We found that age at menarche (PR = 0.77, 95%CI: 0.63-0.96), having negative Rh blood type (PR = 4.43, 95%CI: 1.95 to 10.08), being moderately depressed or higher (PR = 2.81, 95%CI: 1.24 to 6.36), and consuming caffeine more than three times per week were statistically associated with having Premenstrual Syndrome or Premenstrual Dysphoric Disorder after adjusting for other variables. CONCLUSION: The prominent risk factors for Premenstrual Syndrome and Premenstrual Dysphoric Disorder were negative Rhesus blood type, menarche age, caffeine consumption, and self-reported depression.
Subject(s)
Premenstrual Dysphoric Disorder , Premenstrual Syndrome , Students, Medical , Humans , Female , Premenstrual Dysphoric Disorder/epidemiology , Premenstrual Dysphoric Disorder/etiology , Cross-Sectional Studies , Caffeine , Premenstrual Syndrome/epidemiologyABSTRACT
Whether a history of premenstrual dysphoric disorder (PMDD) is associated with a subsequent risk of major affective disorders remains unclear. This study aimed to examine the risk of unipolar depression and bipolar disorder in women with PMDD compared with those without PMDD. This study used data from the Taiwan National Health Insurance Research Database. Women who were diagnosed with PMDD and had no history of any major affective disorder were included. The controls were women without PMDD matched for demographics and physical and psychiatric comorbidities. Cox regression was used to estimate the risk of unipolar depression and bipolar disorder. We included 8222 women with PMDD and 32,888 matched controls. After adjusting for potential confounders, we found that the women with PMDD were associated with a higher risk of unipolar depression [hazard ratio (HR) 2.58; 95 % confidence interval (CI), 2.23-2.98] and bipolar disorder (HR 2.50; 95 % CI 1.62-3.88) than the controls. The PMDD group had a younger age at the diagnosis of unipolar depression (37.11 vs 41.59 years) and bipolar disorder (35.59 vs 42.02 years, p = 0.002), and shorter duration between enrollment and onset of unipolar depression (2.97 vs 5.33 years, p < 0.001) and bipolar disorder (3.05 vs 5.57 years, p < 0.001). Our results showed a strong association between PMDD and major affective disorders. Healthcare workers should be aware of patients with PMDD and the risk of developing major affective mental disorders.
Subject(s)
Bipolar Disorder , Depressive Disorder, Major , Premenstrual Dysphoric Disorder , Humans , Female , Male , Premenstrual Dysphoric Disorder/diagnosis , Premenstrual Dysphoric Disorder/epidemiology , Longitudinal Studies , Depressive Disorder, Major/epidemiology , Comorbidity , Bipolar Disorder/diagnosis , Bipolar Disorder/epidemiology , Bipolar Disorder/complicationsABSTRACT
INTRODUCTION: Premenstrual dysphoric disorder (PMDD) is a prevalent psychiatric condition associated with substantial mental distress, impaired psychosocial functioning, high rates of co-morbid psychiatric conditions, and elevated risk of suicide. AREAS COVERED: We provide an update on epidemiology, pathophysiology, clinical presentation, and diagnosis of PMDD, with a focus on the pharmacological management of this condition. EXPERT OPINION: Given the high rates of false positives from retrospective assessments, prospective daily symptom monitoring for a minimal of two symptomatic menstrual cycles is critical to accurately confirm (or rule out) the diagnosis of PMDD. Serotonin-based antidepressants are well-established first-line treatments of PMDD. Second-line treatment includes the use of combined, monophasic oral contraceptives. In mild to moderate cases, independent meta-analyses have shown efficacy of Chasteberry extract (Vitex agnus cactus). Preliminary results with compounds blocking the synthesis of allopregnanolone are promising.
Subject(s)
Premenstrual Dysphoric Disorder , Premenstrual Syndrome , Female , Humans , Premenstrual Dysphoric Disorder/drug therapy , Premenstrual Dysphoric Disorder/epidemiology , Premenstrual Syndrome/diagnosis , Premenstrual Syndrome/drug therapy , Premenstrual Syndrome/epidemiology , Prospective Studies , Retrospective Studies , Contraceptives, Oral, Combined/therapeutic useSubject(s)
Bipolar Disorder , Premenstrual Dysphoric Disorder , Premenstrual Syndrome , Female , Humans , Premenstrual Dysphoric Disorder/diagnosis , Premenstrual Dysphoric Disorder/epidemiology , Bipolar Disorder/diagnosis , Bipolar Disorder/epidemiology , Comorbidity , Premenstrual Syndrome/diagnosis , Premenstrual Syndrome/epidemiologyABSTRACT
Objective: Since depression represents the most predominant mood polarity in bipolar disorder (BD), the prevalence rates of a diagnosis of premenstrual dysphoric disorder (PMDD) in women with BD and those of a diagnosis of BD in women with PMDD deserve systematic review.Data Sources: A systematic search of PubMed, EMBASE, CINAHL, PsycINFO, and Cochrane Reviews databases was carried out on November 19, 2021, using the terms [late luteal phase disorder OR premenstrual dysphoric disorder] AND comorbidity AND bipolar disorder. Articles from 1987-2021 were searched. Case studies, intervention studies, reviews, and systematic analyses were excluded.Study Selection: All studies that included a diagnosis of PMDD and BD were included.Data Extraction: The selected articles were reviewed to extract data using a data extraction form developed for this study.Results: A total of 5 studies were included in the review. Extant literature, although limited, suggests that PMDD is more common among women with BD than in the general population. Similarly, BD is more common among women with PMDD than in the general population. The proportion of people with PMDD and diagnosed with BD ranged from 10% to 15%. Conversely, the proportion of people with BD who received a diagnosis of PMDD ranged from 27% to 76%.Conclusions: Only a small number of relevant studies were available, and the findings from these were limited by the failure to employ prospective monitoring of symptoms-perhaps the most important feature necessary for confirming PMDD and differentiating it from premenstrual exacerbation of BD. Given the important clinical and heuristic implications, prospective studies are needed to clarify the relationship between the two disorders in order to improve their detection, diagnosis, and treatment.
Subject(s)
Bipolar Disorder , Premenstrual Dysphoric Disorder , Premenstrual Syndrome , Humans , Female , Premenstrual Dysphoric Disorder/diagnosis , Premenstrual Dysphoric Disorder/epidemiology , Premenstrual Dysphoric Disorder/drug therapy , Bipolar Disorder/diagnosis , Bipolar Disorder/epidemiology , Premenstrual Syndrome/diagnosis , Premenstrual Syndrome/epidemiology , Premenstrual Syndrome/therapy , Prospective Studies , Luteal PhaseABSTRACT
Premenstrual Syndrome (PMS) comprises psychological, somatic, and behavioral symptoms during the luteal phase of almost every menstrual cycle. PMS and premenstrual dysphoric disorder (PMDD) may be associated with substance use. Between 2018 and 2020 we studied the relationship between PMS and substance use within a prospective case-control design comparing a consecutive series of women having a substance use disorder and being treated in an addiction treatment center (ATC group, n = 151)) and one with community dwelling women attending their general practitioner (GP group, n = 101). The psychoactive substance use disorder women in the ATC were most frequently treated for was alcohol (39.7 percent), cannabis (20.5) and cocaine 7.9 percent) respectively. The relationship between PMS, problematic alcohol use, and craving for alcohol was explored with the Alcohol Use Disorders Identification Test (AUDIT), Premenstrual Screening Symptoms Tool (PSST), and Penn Alcohol Craving Scale (PACS). Descriptive analyses were used to report demographic variables, and the prevalence and nature of SUD according to DSM-5 and PMS in the two study populations and a two-step multiple hierarchical linear regression to assess the contribution of the variance of the AUDIT and PSST to craving, as measured with PACS. The frequency of PMS and PMDD is significantly higher in the ATC group than in the GP group (48.3 versus 26.7 percent and 16.6 versus 5.9 percent). Craving in the ATC group is better predicted (50 percent) by alcohol-related problems as measured by the AUDIT than in the GP group (25 percent). PMS complaints do contribute to craving in ATC group and not in GP group. There is a high prevalence of PMS/PMDD in the population with a substance use disorder. If these patients with PMS symptoms experience higher levels of craving, it may increase the risk of substance use relapse.
Subject(s)
Alcoholism , Premenstrual Dysphoric Disorder , Premenstrual Syndrome , Substance-Related Disorders , Craving , Female , Humans , Premenstrual Dysphoric Disorder/epidemiology , Premenstrual Dysphoric Disorder/psychology , Premenstrual Syndrome/psychology , Substance-Related Disorders/epidemiologyABSTRACT
BACKGROUND: Suicide is the second leading cause of death among Americans ages 10 to 34, with alarming recent increases in suicide rates among those assigned female at birth. A large body of evidence points to menstrual cycle influences on self-injurious thoughts and behaviors (STBs), suggesting that neurobiological hormone sensitivities, such as in premenstrual dysphoric disorder (PMDD), may drive suicide risk in females. However, existing studies of STBs in PMDD use cross-sectional self-report measures of PMDD with poor validity. As a first step to establish accurate prevalence rates of STBs in PMDD, we examined the lifetime prevalence of STBs in a large global survey of patients reporting a diagnosis of PMDD based on daily ratings. METHOD: Individuals with self-reported PMDD symptoms were invited to an online survey through online support groups for PMDD and social media posts from PMDD awareness accounts. Participants reported demographics, whether they had been diagnosed with PMDD by a healthcare provider using daily ratings, STBs using the Columbia Suicide Severity Rating Scale, and history of lifetime comorbid psychiatric diagnoses. RESULTS: Of 2,689 survey completers, 599 (23%) reported a diagnosis with PMDD based on two months of daily ratings and were included in analyses. We observed high rates of lifetime active suicidal ideation (72%), planning (49%), intent (42%), preparing for an attempt (40%), and attempt (34%), as well as non-suicidal self-injury (51%). The majority (70%) of the sample reported at least one lifetime comorbid psychiatric diagnosis. Predictors of lifetime active suicidal ideation included nulliparity, low-to-moderate (vs. high) income, and history of diagnosis with major depression or post-traumatic stress disorder. Predictors of lifetime attempts among those reporting lifetime active ideation included older age, nulliparity, lower income, and history of diagnosis with post-traumatic stress disorder or borderline personality disorder. CONCLUSIONS: These data indicate high rates of STBs among those reporting prospective diagnosis of PMDD and highlight the need for prospective research on mechanisms and prevention of STBs in PMDD. Clinical practice guidelines for PMDD should accommodate comorbidities and recommend frequent screenings for STB risk. STBs should be considered for inclusion in future iterations of the DSM PMDD diagnostic criteria.
Subject(s)
Premenstrual Dysphoric Disorder , Premenstrual Syndrome , Adolescent , Adult , Child , Cross-Sectional Studies , Female , Humans , Infant, Newborn , Premenstrual Dysphoric Disorder/diagnosis , Premenstrual Dysphoric Disorder/epidemiology , Premenstrual Dysphoric Disorder/psychology , Premenstrual Syndrome/diagnosis , Premenstrual Syndrome/epidemiology , Premenstrual Syndrome/psychology , Prevalence , Prospective Studies , Young AdultABSTRACT
BACKGROUND: Although previous studies report an association between Premenstrual Dysphoric Disorder (PMDD) and suicidal ideation, most studies have only established a provisional and retrospective diagnosis of PMDD fundamentally invalidating the diagnosis. Therefore, the aim of this study was to describe the prevalence and to explore correlates of current suicidal ideation in the late luteal phase in women with prospectively assessed and confirmed PMDD. METHODS: Participants were 110 women who attended the pre-randomization baseline visit of two randomized placebo-controlled clinical trials between January 15, 2017 and October 19, 2019. PMDD was diagnosed prospectively in line with DSM-5 criteria. Current suicidal ideation was measured by the MADRS-S in the late luteal phase. Descriptive statistics were presented and logistic regression analyses were carried out to explore the association between psychosocial and health characteristics and current suicidal ideation, presenting unadjusted odds ratios (OR) and 95% confidence intervals (CI). RESULTS: Current suicidal ideation was reported by nearly 40% of women with confirmed PMDD (n = 43, 39.1%). Previous psychological treatment for PMDD and higher depressive symptoms in the late luteal phase were positively associated with current suicidal ideation (OR 5.63, 95% CI 1.07-29.49, and OR 1.17, 95% CI 1.10-1.25, respectively), whereas higher ratings of self-rated health were associated with lower odds ratios for current suicidal ideation (OR 0.98, 95% CI 0.96-0.99). CONCLUSIONS: A substantial proportion of women with confirmed PMDD report current suicidal ideation in the late luteal phase. Results point to a need for better awareness and screening of suicidal ideation in women with PMDD.